Isocarboxazid chemical structure
Find information on thousands of medical conditions and prescription drugs.

Isocarboxazid

Isocarboxazid is a nonselective hydrazine-derived monoamine oxidase inhibitor used in treatment resistant depression. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Uses

Approved

In the United States, isocarboxazid is approved for the treatment of depression.

Off-Label/Unapproved/Investigational

A randomized controlled trial published in December of 1988 found that isocarboxazid significantly reduced bingeing and purging in bulimia nervosa, regardless of the presence or absence of depression or personality disorder.

Brand Names

United States

MARPLANĀ® by Hoffmann-La Roche, starting in 1959 and discontinuing in 1994. After much patient and physician outcry, they resumed manufacturing just enough MarplanĀ® to distribute on an as-needed basis. In October of 1998, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc. announced that Oxford, "is acquiring ownership of the NDA for the antidepressant product MarplanĀ® (isocarboxazid) from Roche."

The maximum daily dose of isocarboxazid is 60mg.

Read more at Wikipedia.org


[List your site here Free!]


Depression in the Long-Term Care Setting
From American Family Physician, 5/15/02 by Grace Brooke Huffman

Elderly patients living in the nursing home setting are up to five times more likely to have depression, but fewer than one fourth are adequately treated. Physicians may believe that other medical conditions are causing the depression or that other medical conditions may make treatment of depression contraindicated. In addition, there is little evidence about the optimal treatment of depression in elderly patients. Brown and associates performed a cross-sectional study and describe management of this condition.

A database used by the Health Care Financing Administration (HCFA) was the source of data for this study. All Medicaid and Medicare-certified nursing homes in Kansas, Maine, Mississippi, New York, and South Dakota were included. Medications given to each resident were recorded, and antidepressants were classified as tricyclics (amitriptyline, imipramine, doxepin, amoxapine, protriptyline, nortriptyline, trimipramine, and desipramine), tetracyclic (maprotiline), selective serotonin reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine), monoamine oxidase inhibitors (phenelzine, isocarboxazid, and tranylcypromine), and others (venlafaxine, trazodone, bupropion, and nefazodone).

Of the 428,055 residents included in the study, 46,677 were diagnosed with depression. The diagnosis occurred more often in women than in men and more often in non-Hispanic white patients than those with other ethnic backgrounds. One half (55 percent) of those with this diagnosis received an antidepressant. Many of these patients were given less than the manufacturer's recommended dosage, although the authors acknowledge that some of the antidepressants may have been prescribed for indications other than depression.

Patients who were 85 years of age or older were less likely to be given treatment than younger patients, and blacks were less likely to be given treatment than whites. Patients with cancer or more than six diagnosed clinical conditions were less likely to take antidepressants. On the other hand, patients with diabetes mellitus or cerebrovascular disease were more likely to receive antidepressants.

The authors concur with the recommendations of the National Institutes of Health Consensus Development Conference on Diagnosis and Treatment of Depression in Late Life, that elderly patients with depression should be given adequate dosages of antidepressants and continue taking them for an appropriate length of time to maximize the likelihood of recovery. Up to 80 percent of these patients respond well to such treatment.

Physicians should be aware that, in the elderly patient, depression may be difficult to distinguish from other conditions (such as dementia), and patients may present with symptom profiles that are different from those of younger patients. Finally, elderly patients may not have full-blown depression but, in this population, a symptom complex representing subsyndromal depression may be amenable to treatment.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Isocarboxazid
Home Contact Resources Exchange Links ebay